Baxano Surgical Inc (BAXS) 0.69 $BAXS
Baxano Surgical, Inc. Reports Operating Results for the First Quarter of 2014, Issues Second Quarter 2014 Guidance
GlobeNewswire - Thu May 08, 3:48PM CDT
- First quarter revenue was $4.4 million -
Baxano Surgical, Inc. Schedules First Quarter 2014 Results Conference Call for Thursday, May 8, 2014
GlobeNewswire - Fri Apr 25, 9:42AM CDT
Baxano Surgical, Inc. (Nasdaq:BAXS) announced today that it plans to release first quarter 2014 financial and operating results after market close on Thursday, May 8, 2014. Ken Reali, President and Chief Executive Officer and Tim Shannon, Chief Financial Officer, will host a conference call starting at 4:30 pm ET on the same day. To listen to the conference call on your telephone, please dial (877) 312-8823 for domestic callers and (253) 237-1182 for international callers approximately ten minutes prior to the start time. The call will be concurrently webcast. To access the live audio broadcast or archived recording, use the following link at http://ir.baxanosurgical.com/events.cfm.
Baxano Surgical, Inc. Announces Closing of $10 Million Private Placement of Convertible Debentures
GlobeNewswire - Wed Apr 23, 6:30AM CDT
Baxano Surgical, Inc. (Nasdaq:BAXS) ("Baxano Surgical" or the "Company"
, a medical device company focused on designing, developing and marketing minimally invasive products to treat degenerative conditions of the spine affecting the lumbar region, announced today the closing of its private placement of approximately $10 million aggregate principal amount of subordinated convertible debentures and warrants to purchase 9,428,000 shares of common stock to entities affiliated with two institutional investors.
Baxano Surgical, Inc. (BAXS) in Focus: Stock up 10.7% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Apr 11, 7:44AM CDT
Baxano Surgical, Inc. was a big mover last session, as the company saw its shares rise nearly 11% on the day.
Why Baxano Surgical (BAXS) Stock Is Higher Today
at The Street - Thu Apr 10, 10:08AM CDT
Shares of Baxano Surgical (BAXS) is up 9.75% to $1.13 today after the company announced that it received FDA clearance for its Avance MIS Pedicle Screw System.
Baxano Surgical Receives 510(k) Clearance for the Avance MIS Pedicle Screw System
GlobeNewswire - Thu Apr 10, 6:30AM CDT
Baxano Surgical, Inc. (Nasdaq:BAXS), a medical device company focused on designing, developing and marketing minimally invasive products to treat degenerative conditions of the lumbar spine, today announced that it has received U.S. Food and Drug Administration 510(k) clearance (k133743) of its Avance(TM) MIS Pedicle Screw System, which may be used as an adjunct to fusion in numerous degenerative and complex spinal pathologies. The innovative design of Avance provides a quick and easy-to-use, percutaneous pedicle screw system that addresses single, complex and multi-level spinal pathologies with minimal tissue disruption and trauma. The Avance system will be in limited market release in the second and third quarter of 2014 and is planned for full launch in the fourth quarter of 2014.
Baxano Surgical, Inc. Announces Changes to Executive Management Team
GlobeNewswire - Fri Mar 14, 11:00AM CDT
Baxano Surgical, Inc. (Nasdaq:BAXS), a medical device company focused on designing, developing and marketing minimally invasive products to treat degenerative conditions of the spine affecting the lumbar region, today announced changes to its executive management team.
Baxano Surgical, Inc. Announces $10 Million Private Placement of Convertible Debentures
GlobeNewswire - Tue Mar 11, 6:30AM CDT
Baxano Surgical, Inc. (Nasdaq:BAXS) ("Baxano Surgical" or the "Company" , a medical device company focused on designing, developing and marketing minimally invasive products to treat degenerative conditions of the spine affecting the lumbar region, announced today that it has entered into a definitive agreement with entities affiliated with two institutional investors in connection with a private placement of approximately $10 million aggregate principal amount of subordinated convertible debentures and warrants to purchase 9,428,000 shares of common stock. Prior to the closing of the private placement, the Company is required to obtain stockholder approval to increase the total number of its authorized shares of common stock and to approve the issuance of common stock pursuant to the debentures and warrants.
Baxano Surgical Announces Participation in Canaccord Genuity Musculoskeletal Conference
GlobeNewswire - Fri Mar 07, 6:30AM CST
Baxano Surgical, Inc. (Nasdaq:BAXS) announced today that it will participate in the Canaccord Genuity Musculoskeletal Conference on March 11, 2014.
Baxano Surgical, Inc. Reports Operating Results for the Fourth Quarter of 2013, Issues First Quarter 2014 Guidance
GlobeNewswire - Fri Mar 07, 2:59AM CST
- Fourth Quarter Revenue Was $6.0 Million -
Baxano Surgical Schedules Fourth Quarter 2013 Results Conference Call for Thursday, March 6, 2014
GlobeNewswire - Mon Mar 03, 6:30AM CST
Baxano Surgical, Inc. (Nasdaq:BAXS) announced today that it plans to release fourth quarter 2013 financial and operating results after market close on Thursday, March 6, 2014. Ken Reali, President and Chief Executive Officer of Baxano Surgical, and Tim Shannon, Interim Chief Financial Officer, will host a conference call starting at 4:30 pm ET on the same day. To listen to the conference call on your telephone, please dial (877) 312-8823 for domestic callers and (253) 237-1182 for international callers approximately ten minutes prior to the start time. The call will be concurrently webcast. To access the live audio broadcast or archived recording, use the following link at http://ir.baxanosurgical.com/events.cfm.
Baxano Surgical Sets Date of 2014 Annual Meeting
GlobeNewswire - Fri Feb 07, 11:30AM CST
Baxano Surgical, Inc. (Nasdaq:BAXS), a medical device company focused on designing, developing and marketing minimally invasive products to treat degenerative conditions of the spine affecting the lumbar region, today announced that it will be holding its Annual Meeting of Stockholders on Thursday, April 17, 2014. Stockholders of record at the close of business on Monday, March 10, 2014 will be entitled to notice of and to vote at the Annual Meeting.
Chimerix (CMRX) Jumps: Stock Adds 8.0% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Jan 31, 7:51AM CST
Chimerix, Inc. was a big mover last session, as its shares rose just over 8% on the day.
Cardica Inc. (CRDC) in Focus: Stock Moves 5.9% Higher - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Jan 29, 8:18AM CST
Cardica Inc. (CRDC) was a big mover last session, as the company saw its shares rise by almost 6% on the day.
Baxano Surgical (BAXS) Shares March Higher, Can It Continue? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Jan 20, 8:54AM CST
Baxano Surgical (BAXS) Shares March Higher, Can It Continue?
4 Under-$10 Health Care Stocks Moving Higher
at The Street - Fri Jan 17, 6:00AM CST
When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.
Baxano Surgical Announces Preliminary Fourth Quarter and Full Year 2013 Unaudited Revenue
GlobeNewswire - Mon Jan 13, 6:30AM CST
Baxano Surgical, Inc. (Nasdaq:BAXS), a medical device company focused on designing, developing and marketing minimally invasive products to treat degenerative conditions of the spine affecting the lumbar region, today announced preliminary unaudited revenue for fourth quarter and full fiscal year 2013 in anticipation of investor meetings in San Francisco during the week of January 13th.
Baxano Surgical (BAXS) Jumps: Stock Adds 7.8% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Jan 06, 7:51AM CST
Baxano Surgical, Inc. was a big mover last session, as its shares rose almost 8% on the day.
Baxano Surgical Announces Final Payment Decision From the Centers for Medicare & Medicaid Services for Pre-Sacral Interbody Fusion
GlobeNewswire - Thu Dec 12, 6:30AM CST
Baxano Surgical, Inc. (Nasdaq:BAXS), a medical device company focused on designing, developing and marketing minimally invasive products to treat degenerative conditions of the spine affecting the lumbar region, today announced the 2014 Medicare Final Physician Fee Schedule Rule released in late November revises upward the Practice Expense Relative Value Units (PERVUs) for Current Procedural Terminology (CPT) Code 22586 for pre-sacral interbody fusion. The total Relative Value Units (RVUs) for CPT Code 22586 are 53.76 in 2014, an 18.8% increase over 2013.
Baxano Surgical Announces Published Clinical Results on Two Core Technologies
GlobeNewswire - Fri Dec 06, 6:30AM CST
Baxano Surgical, Inc. (Nasdaq:BAXS), a medical device company focused on designing, developing and marketing minimally invasive products to treat degenerative conditions of the spine affecting the lumbar region, today announced the publication of two clinical studies focused on two of its core technologies: the AxiaLIF Plus presacral access and interbody fusion system and the iO-Flex minimally invasive decompression instrument. Both studies are featured in the December 1st edition of the Journal of Spinal Disorders and Techniques.
Baxano Surgical, Inc. Reports Operating Results for the First Quarter of 2014, Issues Second Quarter 2014 Guidance
GlobeNewswire - Thu May 08, 3:48PM CDT
- First quarter revenue was $4.4 million -
Baxano Surgical, Inc. Schedules First Quarter 2014 Results Conference Call for Thursday, May 8, 2014
GlobeNewswire - Fri Apr 25, 9:42AM CDT
Baxano Surgical, Inc. (Nasdaq:BAXS) announced today that it plans to release first quarter 2014 financial and operating results after market close on Thursday, May 8, 2014. Ken Reali, President and Chief Executive Officer and Tim Shannon, Chief Financial Officer, will host a conference call starting at 4:30 pm ET on the same day. To listen to the conference call on your telephone, please dial (877) 312-8823 for domestic callers and (253) 237-1182 for international callers approximately ten minutes prior to the start time. The call will be concurrently webcast. To access the live audio broadcast or archived recording, use the following link at http://ir.baxanosurgical.com/events.cfm.
Baxano Surgical, Inc. Announces Closing of $10 Million Private Placement of Convertible Debentures
GlobeNewswire - Wed Apr 23, 6:30AM CDT
Baxano Surgical, Inc. (Nasdaq:BAXS) ("Baxano Surgical" or the "Company"
, a medical device company focused on designing, developing and marketing minimally invasive products to treat degenerative conditions of the spine affecting the lumbar region, announced today the closing of its private placement of approximately $10 million aggregate principal amount of subordinated convertible debentures and warrants to purchase 9,428,000 shares of common stock to entities affiliated with two institutional investors. Baxano Surgical, Inc. (BAXS) in Focus: Stock up 10.7% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Apr 11, 7:44AM CDT
Baxano Surgical, Inc. was a big mover last session, as the company saw its shares rise nearly 11% on the day.
Why Baxano Surgical (BAXS) Stock Is Higher Today
at The Street - Thu Apr 10, 10:08AM CDT
Shares of Baxano Surgical (BAXS) is up 9.75% to $1.13 today after the company announced that it received FDA clearance for its Avance MIS Pedicle Screw System.
Baxano Surgical Receives 510(k) Clearance for the Avance MIS Pedicle Screw System
GlobeNewswire - Thu Apr 10, 6:30AM CDT
Baxano Surgical, Inc. (Nasdaq:BAXS), a medical device company focused on designing, developing and marketing minimally invasive products to treat degenerative conditions of the lumbar spine, today announced that it has received U.S. Food and Drug Administration 510(k) clearance (k133743) of its Avance(TM) MIS Pedicle Screw System, which may be used as an adjunct to fusion in numerous degenerative and complex spinal pathologies. The innovative design of Avance provides a quick and easy-to-use, percutaneous pedicle screw system that addresses single, complex and multi-level spinal pathologies with minimal tissue disruption and trauma. The Avance system will be in limited market release in the second and third quarter of 2014 and is planned for full launch in the fourth quarter of 2014.
Baxano Surgical, Inc. Announces Changes to Executive Management Team
GlobeNewswire - Fri Mar 14, 11:00AM CDT
Baxano Surgical, Inc. (Nasdaq:BAXS), a medical device company focused on designing, developing and marketing minimally invasive products to treat degenerative conditions of the spine affecting the lumbar region, today announced changes to its executive management team.
Baxano Surgical, Inc. Announces $10 Million Private Placement of Convertible Debentures
GlobeNewswire - Tue Mar 11, 6:30AM CDT
Baxano Surgical, Inc. (Nasdaq:BAXS) ("Baxano Surgical" or the "Company"
, a medical device company focused on designing, developing and marketing minimally invasive products to treat degenerative conditions of the spine affecting the lumbar region, announced today that it has entered into a definitive agreement with entities affiliated with two institutional investors in connection with a private placement of approximately $10 million aggregate principal amount of subordinated convertible debentures and warrants to purchase 9,428,000 shares of common stock. Prior to the closing of the private placement, the Company is required to obtain stockholder approval to increase the total number of its authorized shares of common stock and to approve the issuance of common stock pursuant to the debentures and warrants. Baxano Surgical Announces Participation in Canaccord Genuity Musculoskeletal Conference
GlobeNewswire - Fri Mar 07, 6:30AM CST
Baxano Surgical, Inc. (Nasdaq:BAXS) announced today that it will participate in the Canaccord Genuity Musculoskeletal Conference on March 11, 2014.
Baxano Surgical, Inc. Reports Operating Results for the Fourth Quarter of 2013, Issues First Quarter 2014 Guidance
GlobeNewswire - Fri Mar 07, 2:59AM CST
- Fourth Quarter Revenue Was $6.0 Million -
Baxano Surgical Schedules Fourth Quarter 2013 Results Conference Call for Thursday, March 6, 2014
GlobeNewswire - Mon Mar 03, 6:30AM CST
Baxano Surgical, Inc. (Nasdaq:BAXS) announced today that it plans to release fourth quarter 2013 financial and operating results after market close on Thursday, March 6, 2014. Ken Reali, President and Chief Executive Officer of Baxano Surgical, and Tim Shannon, Interim Chief Financial Officer, will host a conference call starting at 4:30 pm ET on the same day. To listen to the conference call on your telephone, please dial (877) 312-8823 for domestic callers and (253) 237-1182 for international callers approximately ten minutes prior to the start time. The call will be concurrently webcast. To access the live audio broadcast or archived recording, use the following link at http://ir.baxanosurgical.com/events.cfm.
Baxano Surgical Sets Date of 2014 Annual Meeting
GlobeNewswire - Fri Feb 07, 11:30AM CST
Baxano Surgical, Inc. (Nasdaq:BAXS), a medical device company focused on designing, developing and marketing minimally invasive products to treat degenerative conditions of the spine affecting the lumbar region, today announced that it will be holding its Annual Meeting of Stockholders on Thursday, April 17, 2014. Stockholders of record at the close of business on Monday, March 10, 2014 will be entitled to notice of and to vote at the Annual Meeting.
Chimerix (CMRX) Jumps: Stock Adds 8.0% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Jan 31, 7:51AM CST
Chimerix, Inc. was a big mover last session, as its shares rose just over 8% on the day.
Cardica Inc. (CRDC) in Focus: Stock Moves 5.9% Higher - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Jan 29, 8:18AM CST
Cardica Inc. (CRDC) was a big mover last session, as the company saw its shares rise by almost 6% on the day.
Baxano Surgical (BAXS) Shares March Higher, Can It Continue? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Jan 20, 8:54AM CST
Baxano Surgical (BAXS) Shares March Higher, Can It Continue?
4 Under-$10 Health Care Stocks Moving Higher
at The Street - Fri Jan 17, 6:00AM CST
When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.
Baxano Surgical Announces Preliminary Fourth Quarter and Full Year 2013 Unaudited Revenue
GlobeNewswire - Mon Jan 13, 6:30AM CST
Baxano Surgical, Inc. (Nasdaq:BAXS), a medical device company focused on designing, developing and marketing minimally invasive products to treat degenerative conditions of the spine affecting the lumbar region, today announced preliminary unaudited revenue for fourth quarter and full fiscal year 2013 in anticipation of investor meetings in San Francisco during the week of January 13th.
Baxano Surgical (BAXS) Jumps: Stock Adds 7.8% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Jan 06, 7:51AM CST
Baxano Surgical, Inc. was a big mover last session, as its shares rose almost 8% on the day.
Baxano Surgical Announces Final Payment Decision From the Centers for Medicare & Medicaid Services for Pre-Sacral Interbody Fusion
GlobeNewswire - Thu Dec 12, 6:30AM CST
Baxano Surgical, Inc. (Nasdaq:BAXS), a medical device company focused on designing, developing and marketing minimally invasive products to treat degenerative conditions of the spine affecting the lumbar region, today announced the 2014 Medicare Final Physician Fee Schedule Rule released in late November revises upward the Practice Expense Relative Value Units (PERVUs) for Current Procedural Terminology (CPT) Code 22586 for pre-sacral interbody fusion. The total Relative Value Units (RVUs) for CPT Code 22586 are 53.76 in 2014, an 18.8% increase over 2013.
Baxano Surgical Announces Published Clinical Results on Two Core Technologies
GlobeNewswire - Fri Dec 06, 6:30AM CST
Baxano Surgical, Inc. (Nasdaq:BAXS), a medical device company focused on designing, developing and marketing minimally invasive products to treat degenerative conditions of the spine affecting the lumbar region, today announced the publication of two clinical studies focused on two of its core technologies: the AxiaLIF Plus presacral access and interbody fusion system and the iO-Flex minimally invasive decompression instrument. Both studies are featured in the December 1st edition of the Journal of Spinal Disorders and Techniques.
